FDA OTC Switch Policy: Key Issue Is Crafting Labeling From Public Domain
Executive Summary
FDA is considering holding a public meeting to discuss Rx-to-OTC switch issues to clarify the agency's current thinking on which prescription categories have the potential to move over-the-counter in the near future
You may also be interested in...
Antihistamine OTC Switch: WellPoint Will Not Sue If FDA Refuses Petition
WellPoint will not take legal action against FDA should the agency reject the health insurer's citizen petition to force an OTC switch of prescription low- and non-sedating antihistamines
Pfizer Rx-To-OTC Comments: Study Before You Switch
FDA should evaluate whether nonprescription Claritin has increased access and lowered costs for allergy sufferers before deciding whether to force the OTC switch of other second-generation antihistamines, Pfizer asserts in May 7 comments to the agency
Pfizer Rx-To-OTC Comments: Study Before You Switch
FDA should evaluate whether nonprescription Claritin has increased access and lowered costs for allergy sufferers before deciding whether to force the OTC switch of other second-generation antihistamines, Pfizer asserts in May 7 comments to the agency